Asia Myelodysplastic Syndrome (MDS) Registry

NCT07355478 | Not Yet Recruiting FDA Drug

• 1 other identifier: CA056-1131
• Study Type: observational
• Target: 500
• Locations: 3 countries
• Sites: 3

Brief Summary

The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.

Conditions

Myelodysplastic Syndromes (MDS)

Keywords

Myelodysplastic syndromes (MDS)

Outcome Measures

Primary Outcomes (33)

• Participant age

  Baseline

• Participant sex

  Baseline

• Participant race

  Baseline

• Participant weight

  Baseline

• Participant height

  Baseline

• Participant body mass index (BMI)

  Baseline

• Participant smoking status

  Baseline

• Participant drinking status

  Baseline

• Family history of MDS or other hematopoietic cancers

  Baseline

• Participant myelodysplastic syndromes diagnosis information

  Baseline

• Participant Eastern Cooperative Oncology Group (ECOG) Performance status at diagnosis

  Baseline

• Participant comorbidities at diagnosis

  Baseline

• Participant Charlson comorbidity index (CCI) score at diagnosis

  Baseline

• Prior clinical diagnosis of other cancers

  Baseline

• Prior clinical diagnosis of hematological diseases

  Baseline

• Anemia status at diagnosis

  Bseline

• Thrombocytopenia status at diagnosis

  Baseline

• Neutropenia status at diagnosis

  Baseline

• Iron overload status at diagnosis

  Baseline

• Red blood cell (RBC) transfusion dependence status at diagnosis

  Baseline

• International Prognostic Scoring System (IPSS) score at diagnosis

  Baseline

• Revised International Prognostic Scoring System (IPSS-R) score at diagnosis

  Baseline

• Molecular International Prognostic Scoring System (IPSS-M) score at diagnosis

  Baseline

• Bone marrow aspirate results

  Baseline and up to 2-years

• Presence of dysplasia

  Baseline and up to 2-years

• Cytogenetic test results

  Baseline and up to 2-years

• Mutation test results at diagnosis

  Baseline

• Complete blood count test results at diagnosis

  Baseline

• Mean corpuscular volume (MCV)

  Baseline and up to 2-years

• C-reactive protein (CRP)

  Baseline and up to 2-years

• Serum ferritin (SF) level

  Baseline and up to 2-years

• Serum erythropoietin levels

  Baseline and up to 2-years

• Lactate dehydrogenase (LDH)

  Baseline and up to 2-years

Secondary Outcomes (12)

• Initial treatment received following diagnosis

  Baseline

• Prior treatments and concomitant medications received

  Baseline

• Subsequent treatments received

  Up to 2-years

• Time from diagnosis to treatment initiation

  Baseline

• Treatment duration

  Up to 2-years

Study Arms (1)

Group 1

Participants diagnosed with myelodysplastic syndromes (MDS)

Drug: Prescribed treatments for myelodysplastic syndromes (MDS)

Interventions

Prescribed treatments for myelodysplastic syndromes (MDS) DRUG

According to the product label

Group 1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The registry will include adults who were/are newly diagnosed with myelodysplastic syndromes (MDS) in Asia (Singapore, South Korea and Taiwan).

You may qualify if:

• Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants:
• Aged at least 18 years at initial diagnosis of MDS
• Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
• Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate
• Aged at least 18 years at initial diagnosis of MDS; and
• Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and
• Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate

You may not qualify if:

• None

Sponsors & Collaborators

• Bristol-Myers Squibb: lead

Study Sites (3)

Local Institution - 0003

Singapore, 169608, Singapore

Location

Local Institution - 002

Seoul, Seoul Teugbyeolsi, 03080, South Korea

Location

Local Institution - 0001

Taipei, 100229, Taiwan

Location

Related Links

• BMS Clinical Trial Information
• FDA Safety Alerts and Recalls

MeSH Terms

Conditions

Myelodysplastic Syndromes

Condition Hierarchy (Ancestors)

Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Bristol Myers Squibb

  Bristol-Myers Squibb

  STUDY DIRECTOR

• Bristol-Myers Squibb

  Bristol-Myers Squibb

  STUDY DIRECTOR

Central Study Contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

855-907-3286; Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

CONTACT

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 2 Years
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 28, 2025
• First Posted: January 21, 2026
• Study Start: March 26, 2026
• Primary Completion (Estimated): October 31, 2026
• Study Completion (Estimated): September 30, 2027
• Last Updated: February 13, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1); KR (1); SG (1)